LB Pharma targets $267M raise in IPO

LB Pharmaceuticals, a neuropsychiatric disease biotech, hopes to raise up to $267 million in an IPO.

Why it matters: LB's offering would be the first biotech IPO in at least six months as the industry battles unique financial and policy headwinds.